AbCellera Biologics (ABCL) Research & Development: 2020-2023
Historic Research & Development for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $48.6 million.
- AbCellera Biologics' Research & Development rose 72.14% to $48.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $175.7 million, marking a year-over-year increase of 62.83%. This contributed to the annual value of $167.3 million for FY2024, which is 4.78% down from last year.
- According to the latest figures from Q4 2023, AbCellera Biologics' Research & Development is $48.6 million, which was up 28.23% from $37.9 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Research & Development registered a high of $52.6 million during Q1 2023, and its lowest value of $4.1 million during Q1 2020.
- Its 3-year average for Research & Development is $28.8 million, with a median of $26.6 million in 2022.
- Data for AbCellera Biologics' Research & Development shows a peak YoY skyrocketed of 199.95% (in 2021) over the last 5 years.
- Over the past 4 years, AbCellera Biologics' Research & Development (Quarterly) stood at $8.6 million in 2020, then skyrocketed by 99.27% to $17.2 million in 2021, then spiked by 64.13% to $28.2 million in 2022, then soared by 72.14% to $48.6 million in 2023.
- Its last three reported values are $48.6 million in Q4 2023, $37.9 million for Q3 2023, and $36.5 million during Q2 2023.